Syndesis Health & LaCardio Sign Research Collaboration Agreement

NEW YORK, NY / ACCESSWIRE / May 11, 2023 / Syndesis Health announced today that it has signed a research collaboration and information sharing agreement with Fundación Cardio Infantil Instituto de Cardiología (LaCardio), a leading cardiovascular hospital in Bogotá, Colombia. LaCardio is joining the Syndesis Health Network alongside progressive healthcare institutions from South America, Asia, […]

NEW YORK, NY / ACCESSWIRE / May 11, 2023 / Syndesis Health announced today that it has signed a research collaboration and information sharing agreement with Fundación Cardio Infantil Instituto de Cardiología (LaCardio), a leading cardiovascular hospital in Bogotá, Colombia.

LaCardio is joining the Syndesis Health Network alongside progressive healthcare institutions from South America, Asia, and Africa. Syndesis Health created its global network of healthcare partners to enable secure access to a multi-country, real-world data set. Syndesis Health’s global research platform, Syntium, unifies de-identified clinical data from these healthcare partners in a secure, ethical, and compliant manner for the improvement of global health outcomes.

The partnership enables LaCardio to extend its commitment to improving patient outcomes by leveraging the Syndesis Health platform for access to data, analytics, and other technical resources. In addition, the partnership enables the hospital to engage in collaborative research opportunities with peer institutions around the world that are a part of the network.

Hans Godfrey, COO and head of Latin America data partnerships for Syndesis Health, commented: “We believe that the future of healthcare will be data-driven. With LaCardio as a partner in the Syndesis Health Network, we will together expand the potential for real-world data to enable research and treatments in the cardiovascular space.”

Dr. Juan Gabriel Cendales, Executive Director of LaCardio, stated: “One of the strategic priorities of LaCardio as a university hospital and scientific research center is to continue advancing in scientific studies while contributing to the health of the people in Colombia and the region. Having valuable data, evaluating, and applying tools, such as AI, in healthcare allows us to anticipate the needs of the population, evaluate new alternatives and improve the experience of patients and collaborators. This alliance is part of the path in which we are working to be the hospital of the future.”

About Syndesis Health

Syndesis Health accelerates research and innovation for healthcare and life sciences companies. The company was founded on the potential for real-world clinical data to advance medical research, improve patient health outcomes, and inform healthcare policy decisions. The Syndesis Health Network enables secure collaboration amongst member organizations and is powered by Syntium, the Syndesis data platform. Visit our website at https://syndesis.com to learn more.

About LaCardio

Fundación Cardioinfantil-LaCardio is a private, nonprofit institution with 50 years of experience. Founded in 1973 by brothers Reinaldo and Camilo Cabrera Polanía, it is one of the few Colombian institutions accredited by the Joint Commission International and has national accreditation granted by ICONTEC. Since 2015, LaCardio is recognized as a University Hospital by the Intersectoral Committee for Human Talent in Health, in compliance of the Ministries of Health and Education of Colombia. Its commitment to health transcends through its mission: to operate on low-income children with heart problems. The MERCO 2022 ranking positioned LaCardio as the best hospital in Colombia. In 2021, Americaeconomia ranked LaCardio 5th in Latin America, evaluating key processes and indicators, including patient safety & dignity, human capital, capacity, and knowledge management.

Contact Information

Leah Patterson
Chief Marketing Officer
leah.patterson@syndesis.com
+1.646.274.1420

Liliana Milena Toro Sánchez Sánchez
Marketing & Communications
lmtoro@lacardio.org
+3157288712

SOURCE: Syndesis Health

Previous Article

Ukrainian Nuclear Workers Chronicle Impact of War in New Book

Next Article

[INVNT GROUP]™ achieves record global growth, accelerating history-making brand campaigns, strategic partnerships, and humanitarian work.

Related Posts

‫ هدايا العيد من أوبو: قدرات استثنائية في التصوير الضوئي وأحدث التقنيات وأرقى التصاميم المذهلة

–  أروع هدايا العيد من أوبو لتسجيل أجمل الذكريات مع أحبتكم بمناسبة عيد الأضحى المبارك – هواتف فايند إكس5 ورينو7 من أوبو تقدم أفضل قدرات التصوير والتقنيات المتقدمة والتصميم الأنيق دبي، الإمارات العربية المتحدة, 6 يوليو / تموز 2022/PRNewswire/ — أعلنت أوبو، العلامة الرائدة عالمياً في مجال التكنولوجيا، عن توفير خيارات مميزة من الهدايا لجميع […]

هيرو موتوكورب تفتتح وكالة رائدة في دبي

تعزيز التواجد في أسواق الخليج إلى 10 نقاط اتصال للعملاء في خمس دول دبي، الإمارات العربية المتحدة ونيودلهي28 أكتوبر 2021/PRNewswire/ — بهدف تعزيز تواجدها في الإمارات العربية المتحدة ، افتتحت هيرو موتوكورب ليمتد، أكبر مصنع للدراجات النارية والدراجات البخارية في العالم، وكالة حصرية جديدة في دبي. بهدف تعزيز تواجدها في الإمارات العربية المتحدة، بدأت الشركة اليوم […]

TOP RANKED ROSEN LAW FIRM Encourages Energy Transfer LP Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ET

NEW YORK, June 19, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Energy Transfer LP (NYSE: ET) between April 13, 2017 and December 20, 2021, both dates inclusive (the “Class Period”), of the important August 2, 2022 lead plaintiff deadline. SO WHAT: If […]

Ascletis Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-CoV-2 Virus

– Ritonavir oral tablet annual production capacity has been expanded to 100 million tablets and can be further rapidly expanded based on market demand – ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection – ASC11 is an oral direct-acting antiviral drug candidate targeting 3-chymotrypsin like […]